Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters
1 hour ago • Google News
89bio Inc (ETNB)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 1.2B
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
0
52W High
$ 11.84
52W Low
$ 4.16
Dividend Yield
0.00%
Beta
1.27
Technicals
50-Day MA
9.3847
200-Day MA
8.7171
52 Week High
11.84
52 Week Low
4.16
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Employees
93
Headquarters
San Francisco, CA
CEO
Mr. Rohan Palekar
Latest News
Woodline Partners LP Has $5.09 Million Stock Holdings in 89BIO $ETNB - MarketBeat
2 hours ago • Google News